Pfizer Exec Says Shares Bristol Myers' View That Co Has The Ability To Navigate The Impact Of IRA On Eliquis; Eliquis Will Be An Important Drug In Co's Portfolio For The Foreseeable Future, From A Net Present Value Perspective, The Impact Of Ira On...
Pfizer Exec Says Shares Bristol Myers' View That Co Has The Ability To Navigate The Impact Of IRA On Eliquis; Eliquis Will Be An Important Drug In Co's Portfolio For The Foreseeable Future, From A Net Present Value Perspective, The Impact Of Ira On...
輝瑞公司高管表示，與百時美施貴寶公司的看法相同，該公司有能力應對IRA對艾力昔單抗的影響；艾力昔單抗從淨現值的角度來看，在公司組合中將是一種重要的藥物，並將在可預見的未來繼續使用。
Pfizer Exec Says Shares Bristol Myers' View That Co Has The Ability To Navigate The Impact Of IRA On Eliquis; Eliquis Will Be An Important Drug In Co's Portfolio For The Foreseeable Future, From A Net Present Value Perspective, The Impact Of Ira On Pfizer Is Somewhat Muted; Says $1.5B Of Cost Savings Is Only From Phase One Of A Multiple Phase Program
輝瑞高管表示與Bristol Myers一樣，公司有能力應對IRA對艾克替尼的影響。艾克替尼將在未來可見的時間內成爲公司組合中重要的藥品。從淨現值的角度看，IRA對輝瑞的影響有所減輕。他表示，15億美元的成本節約僅來自多階段計劃的第一階段。
- Conf Call
- 電話會議